Filing Flows › Theriva Biologics (TOVX) › Recalls, complaints & regulation
Theriva Biologics (TOVX): clinical trials
Theriva Biologics (TOVX) beyond its filings: 2 active clinical trials.
Theriva Biologics' latest quarter
Theriva Biologics, Q1 2026: revenue $300K, operating margin -709.0%, net loss $2.0M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Theriva Biologics have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.